[go: up one dir, main page]

WO2011030351A3 - Compositions pharmaceutiques au goût masqué - Google Patents

Compositions pharmaceutiques au goût masqué Download PDF

Info

Publication number
WO2011030351A3
WO2011030351A3 PCT/IN2010/000589 IN2010000589W WO2011030351A3 WO 2011030351 A3 WO2011030351 A3 WO 2011030351A3 IN 2010000589 W IN2010000589 W IN 2010000589W WO 2011030351 A3 WO2011030351 A3 WO 2011030351A3
Authority
WO
WIPO (PCT)
Prior art keywords
taste
tablets
pde
pharmaceutical compositions
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2010/000589
Other languages
English (en)
Other versions
WO2011030351A2 (fr
Inventor
Pratibha Sudhir Pilgaonkar
Maharukh Tehmasp Rustomjee
Anilkumar Surendrakumar Gandhi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rubicon Research Pvt Ltd
Original Assignee
Rubicon Research Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Research Pvt Ltd filed Critical Rubicon Research Pvt Ltd
Publication of WO2011030351A2 publication Critical patent/WO2011030351A2/fr
Publication of WO2011030351A3 publication Critical patent/WO2011030351A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques au goût masqué comprenant des inhibiteurs de phosphodiestérase-5 (PDE-5). Lesdites compositions pharmaceutiques au goût masqué pour administration orale comprennent au moins un inhibiteur de PDE-5, au moins un agent masqueur de goût, et au moins un excipient pharmaceutiquement acceptable. En outre, les compositions d'inhibiteur de PDE-5 au goût masqué sont fournies sous la forme de formulations au goût agréable adaptées à une administration orale, telle que des comprimés à désintégration orale, des comprimés à dispersion rapide, des comprimés croquables, des comprimés dispersibles, et des comprimés effervescents ou analogues. L'invention porte en outre sur un procédé de masquage du goût désagréable de l'inhibiteur de PDE-5.
PCT/IN2010/000589 2009-09-03 2010-09-03 Compositions pharmaceutiques au goût masqué Ceased WO2011030351A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2021/MUM/2009 2009-09-03
IN2021MU2009 2009-09-03

Publications (2)

Publication Number Publication Date
WO2011030351A2 WO2011030351A2 (fr) 2011-03-17
WO2011030351A3 true WO2011030351A3 (fr) 2011-06-30

Family

ID=43567799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000589 Ceased WO2011030351A2 (fr) 2009-09-03 2010-09-03 Compositions pharmaceutiques au goût masqué

Country Status (1)

Country Link
WO (1) WO2011030351A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130058160A (ko) * 2011-11-25 2013-06-04 한국유나이티드제약 주식회사 쓴맛이 차폐된 실데나필 시트레이트의 저작정 및 이의 제조방법
MX366768B (es) * 2011-12-08 2019-07-17 Laboratorios Liomont S A De C V Tableta orodispersable de sildenafil y metodo para preparar la misma.
WO2013085276A1 (fr) * 2011-12-08 2013-06-13 에스케이케미칼 주식회사 Film pour administration orale contenant du mirodénafil ou l'un de ses sels pharmaceutiquement acceptables
WO2014092661A1 (fr) * 2012-01-18 2014-06-19 Mahmut Bilgic Formulations particulaires de tadalafil sous forme effervescente
WO2013109221A1 (fr) * 2012-01-18 2013-07-25 Mahmut Bilgic Nouvelles formulations effervescentes comprenant une composition édulcorante
EP2641477B2 (fr) * 2012-03-19 2022-06-08 Symrise AG Compositions de matière
EP2867199B1 (fr) * 2012-07-02 2018-04-18 Hetero Research Foundation Compositions stables de fésotérodine
CN102727455B (zh) * 2012-07-03 2016-06-29 北京科信必成医药科技发展有限公司 一种他达那非口腔崩解片及其制备方法
CN102727456B (zh) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 药物口腔崩解片及其制备方法
KR101953735B1 (ko) * 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
US20140271847A1 (en) * 2013-03-13 2014-09-18 SatisPharma, LLC Formulations and methods for rapid penile erections
US20160287656A1 (en) * 2013-03-20 2016-10-06 Natureceuticals Sdn Bhd Herbaceutical Formulations
CN104352461B (zh) * 2013-04-28 2017-07-14 南京海融医药科技股份有限公司 他达拉非的口服药物制剂
CN103271885A (zh) * 2013-05-23 2013-09-04 浙江华海药业股份有限公司 他达拉非口腔崩解片及其制备方法
US20160095818A1 (en) 2013-06-03 2016-04-07 Mcneil Ab Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity
KR102239291B1 (ko) * 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
CN104644574B (zh) * 2013-11-18 2017-08-01 深圳海王医药科技研究院有限公司 一种枸橼酸西地那非掩味制剂
WO2015089105A1 (fr) * 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
KR101485177B1 (ko) * 2014-02-10 2015-01-23 한국유나이티드제약 주식회사 쓴맛이 차폐된 실데나필 시트레이트의 저작정 및 그 제조방법
CN105213333A (zh) * 2014-06-30 2016-01-06 深圳海王药业有限公司 一种他达拉非药物组合物及其制备方法
KR101561406B1 (ko) * 2015-02-02 2015-10-16 환인제약 주식회사 두타스테라이드 함유 고체 분산체 및 이를 포함하는 조성물
HRP20210543T1 (hr) 2015-07-07 2021-05-14 H. Lundbeck A/S Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti
US10342886B2 (en) 2016-01-26 2019-07-09 S.C. Johnson & Son, Inc. Extruded wax melt and method of producing same
US10010638B2 (en) 2016-06-14 2018-07-03 S. C. Johnson & Son, Inc. Wax melt with filler
US10912778B2 (en) 2016-12-14 2021-02-09 Respira Therapeutics, Inc. Methods for treatment of pulmonary hypertension
CN107694476B (zh) * 2017-07-25 2020-07-10 江苏远鸿新材料科技有限公司 一种高强度球型干燥剂的成型制造方法
EP3700510B1 (fr) * 2017-10-26 2021-10-06 Capsugel Belgium NV Formulations remplies liquides d'inhibiteurs de pde5
IT201800003507A1 (it) * 2018-03-13 2019-09-13 Fulton Medicinali S P A Compressa sublinguale comprendente sildenafil citrato
EP3801526B1 (fr) 2018-05-25 2023-12-27 Imara Inc. Formes cristallines et monohydrate de 6- [(3s,4s)-4-méthyl-1-(pyrimidin-2-ylméthyl) pyrrolidin-3-yl]-3-tétrahydropyran-4-yl-7h-imidazo [1,5-a] pyrazin-8-one
KR102831968B1 (ko) * 2018-08-31 2025-07-08 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
CN111110683B (zh) * 2018-10-31 2023-08-15 广东东阳光药业股份有限公司 一种索利那新掩味组合物及其制备方法
US20220193081A1 (en) * 2019-04-18 2022-06-23 Ellamed Ip & Services Pte. Ltd. Liquid sildenafil citrate compositions
KR102249155B1 (ko) * 2019-07-26 2021-05-07 주식회사 코아팜바이오 유데나필을 함유하는 약제학적 조성물
WO2022216294A1 (fr) 2021-04-09 2022-10-13 Auson Pharmaceuticals Inc. Poudre pour suspension orale contenant du tadalafil
CN114957332A (zh) * 2022-05-30 2022-08-30 苏州正永生物医药有限公司 一种阿伐那非磷酸酯类化合物及其制备方法和应用
IT202200016533A1 (it) * 2022-08-03 2024-02-03 Recordati Ind Chimica E Farmaceutica S P A Complessazione innovativa dell’estratto lipido-sterolico di serenoa con tadalafil.
WO2024158694A1 (fr) * 2023-01-23 2024-08-02 Villya LLC Compositions et méthodes pour améliorer la solubilité d'agents thérapeutiques du dysfonctionnement érectile
WO2024159161A1 (fr) * 2023-01-27 2024-08-02 Bayer Healthcare Llc Masquage de goût avec une barrière physique à composants multiples
CN115990140A (zh) * 2023-02-15 2023-04-21 北京悦康科创医药科技股份有限公司 一种那非类化合物冻干片及其制备方法
CN117243927A (zh) * 2023-10-17 2023-12-19 深圳市泰力生物医药有限公司 含安全有效掩味剂的盐酸卡利拉嗪口溶膜制剂及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017976A1 (fr) * 2002-08-21 2004-03-04 Phoqus Pharmaceuticals Limited, Forme psologique orale a gout masque, a dissolution rapide et comprenant du sildenafil
WO2004087111A1 (fr) * 2003-04-04 2004-10-14 Ranbaxy Laboratories Limited Compositions pharmaceutiques orales a gout masque
WO2006047493A2 (fr) * 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Compositions pharmaceutiques a saveur masquee avec substances porogenes gastrosolubles
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
WO2009074995A1 (fr) * 2007-12-10 2009-06-18 Ajanta Pharma Limited Compositions à croquer de citrate de sildénafil au goût masqué

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900061A (es) 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US7182958B1 (en) 1999-08-03 2007-02-27 Lilly Icos Llc. β-carboline pharmaceutical compositions
JP2008520751A (ja) 2005-02-25 2008-06-19 テバ ファーマシューティカル インダストリーズ リミティド 大粒子サイズを有するタダラフィル及びそれを調製する方法
JP2008546786A (ja) 2005-06-23 2008-12-25 シェーリング コーポレイション Ｐｄｅ５インヒビターの迅速吸収性経口処方物
WO2007027612A2 (fr) 2005-08-29 2007-03-08 Teva Pharmaceutical Industries Ltd. Tadalafil a particules solides a distribution granulometrique bimodale
WO2007033239A2 (fr) 2005-09-13 2007-03-22 Elan Pharma International, Limited Formulations nanoparticulaires de tadalafil
AU2007232098A1 (en) 2006-03-31 2007-10-11 Rubicon Research Private Limited Directly compressible composite for orally disintegrating tablets
RU2009103660A (ru) 2006-07-07 2010-08-20 Тева Фармасьютикал Индастриес Лтд. (Il) Твердые фармацевтические композиции, включающие тадалафил и по меньшей мере один носитель

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017976A1 (fr) * 2002-08-21 2004-03-04 Phoqus Pharmaceuticals Limited, Forme psologique orale a gout masque, a dissolution rapide et comprenant du sildenafil
WO2004087111A1 (fr) * 2003-04-04 2004-10-14 Ranbaxy Laboratories Limited Compositions pharmaceutiques orales a gout masque
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
WO2006047493A2 (fr) * 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Compositions pharmaceutiques a saveur masquee avec substances porogenes gastrosolubles
US20060105039A1 (en) * 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2009074995A1 (fr) * 2007-12-10 2009-06-18 Ajanta Pharma Limited Compositions à croquer de citrate de sildénafil au goût masqué

Also Published As

Publication number Publication date
WO2011030351A2 (fr) 2011-03-17

Similar Documents

Publication Publication Date Title
WO2011030351A3 (fr) Compositions pharmaceutiques au goût masqué
WO2011110939A3 (fr) Compositions pharmaceutiques de benzhydrylpipérazines substituées
MX2008000087A (es) Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
WO2008040534A3 (fr) Formes pharmaceutiques à base de film non muco-adhésif
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
WO2010116385A3 (fr) Compositions pharmaceutiques pour atténuer un goût désagréable
WO2010046933A3 (fr) Compositions pharmaceutiques de linézolid à goût masqué
WO2013183062A3 (fr) Formulations d'ibuprofène de goût agréable
WO2005069933A3 (fr) Procedes permettant de traiter une maladie de type inflammatoire
WO2007005668A3 (fr) Inhibiteurs de bis-aryl kinase et methode associee
WO2008085765A3 (fr) Formes dosifiées de petit volume de médicament contenant du sufentanil s'administrant par voie trans-muqueuse orale pour le traitement de la douleur
WO2007100614A3 (fr) FORMULATION NON CRISTALLINE STABLE COMPRENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE
WO2009084017A3 (fr) Comprimés de chlorhydrate de mémantine à dissolution orale et au goût masqué
WO2009114118A3 (fr) Compositions pharmaceutiques orales de buprénorphine et procédé d’utilisation
WO2008038003A3 (fr) Compositions pharmaceutiques
WO2010011772A3 (fr) Inhibiteurs de la pyrazolopyridine kinase tricyclique
SG166115A1 (en) Pharmaceutical preparation containing meloxicam
AP2008004447A0 (en) Orally absorbed pharmaceutical formulation and method of administration
MX2009007784A (es) Composiciones de tiacumicinas estables.
WO2009045795A3 (fr) Formulations galéniques de composés organiques
WO2008035380A3 (fr) Procédé amélioré de préparation de formotérol de grande pureté et de ses sels pharmaceutiquement acceptables
WO2008001201A3 (fr) Compositions pharmaceutiques de clopidogrel
WO2007131070A3 (fr) Compositions, formes pharmaceutiques et méthodes de traitement des vomissements
WO2010127100A8 (fr) Compositions comprenant un antihistaminique, un antitussif et un décongestionnant dans des formulations à libération prolongée
WO2008081268A3 (fr) Compositions pharmaceutiques d'entacapone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10803268

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10803268

Country of ref document: EP

Kind code of ref document: A2